Ligand id: 9802

Name: CFZ533

Compound class Antibody
CFZ-533 | iscalimab (proposed INN) | NVP-CFZ533 | OM11-62MF
CFZ533 is an anti-CD40 monoclonal antibody that is designed exhibit no agonist activity and is non-depleting (no ADCC activity for an improved safety profile, particularly in non-oncologic indications). It is claimed in Novartis' patent WO2012065950 [1] as mAb1 (based on peptide sequence alignments between the INN record for iscalimab and patented sequences retrieved from a BLAST search). Blocking CD40-mediated inflammatory responses is a well advanced mechanism being expoited for potential to treat autoimmune and inflammatory disorders and/or for preventing/reducing graft rejection following organ transplant.
Database Links
Specialist databases
IMGT/mAb-DB 799
Other databases
GtoPdb PubChem SID 354702274